KP-102 · Pralmorelin
Potent GH secretagogue — strong pulses with appetite stimulation.
FDA
Research Only
WADA
Banned
HALF-LIFE
~1–2 hours
ROUTE
SubQ injection
SCHEDULE
2–3× daily
In Plain English
Potent GH secretagogue — strong pulses with appetite stimulation.
Status & Legality
NATTY?
Not NattyWADA banned substance. Tested athletes will fail.
FDA
Research OnlyFor research purposes only. Not FDA approved.
WADA
BannedOn WADA prohibited list. Use disqualifies in tested sports.
COMPOUNDING
Not from pharmaciesNot available from licensed compounding pharmacies.
PRESCRIBED
Not prescribedNot prescribed in conventional medicine.
ROUTE
SubQ injectionAdministration via subq injection.
GH stimulation
IGF-1 elevation
Muscle growth
GHRP-2 is one of the most potent growth hormone secretagogues available. It stimulates ghrelin receptors to produce strong GH pulses and also mildly elevates cortisol and prolactin. More powerful than Ipamorelin but with more side effects. Preferred by those prioritizing maximum GH release.
Cortisol elevation
Prolactin increase
Hunger/appetite stimulation
Water retention
Headache
Numbness/tingling
Ignoring the cortisol elevation — GHRP-2 raises both cortisol and prolactin, which blunts gains if recovery is poor or training stress is high
Stacking two GHRPs together — pick one GHRP and pair it with a GHRH; combining GHRPs offers no advantage
Not managing the cortisol spike — those with stress-sensitive conditions should default to Ipamorelin
Insulin — GH-driven glucose management requires monitoring during extended cycles
Corticosteroids — additive cortisol effects; avoid combining
Cabergoline — sometimes used to counteract GHRP-2's prolactin elevation; discuss with a prescriber
GHRP-2 produces stronger GH pulses than Ipamorelin but at the cost of cortisol and prolactin elevation. Unless you specifically need maximum GH output and can actively manage the cortisol with good sleep and low stress, Ipamorelin is the cleaner and more manageable choice for most protocols.
Stats
Sources & Studies
Bowers CY. et al., J Clin Endocrinol Metab, 1994